View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
DOJ/DEA RIN: 1117-AB78 Publication ID: Spring 2025 
Title: Expansion of Induction of Buprenorphine via Telemedicine Encounter  
Abstract:

DEA is promulgating regulatory changes which would clarify the rights and obligations for DEA registrants when prescribing buprenorphine to patients with Opioid Use Disorder pursuant to a telemedicine encounter, including those which utilize audio-only telecommunication systems.

 
Agency: Department of Justice(DOJ)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: No  Unfunded Mandates: No 
EO 14192 Designation: Deregulatory 
CFR Citation: 21 CFR 1300    21 CFR 1304    21 CFR 1306   
Legal Authority: 21 U.S.C. 802(54)(G)   
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM  03/01/2023  88 FR 12890   
NPRM Comment Period End  03/31/2023 
Temporary Rule  05/10/2023  88 FR 30037   
Temporary Rule Effective  05/11/2023 
Second Temporary Rule  10/10/2023  88 FR 69879   
Second Temporary Rule Effective  11/11/2023 
Third Temporary Rule  11/24/2024  89 FR 91253   
Third Temporary Rule Effective  01/01/2025 
Final Rule  01/17/2025  90 FR 6504   
Final Rule Delay of Effective Dates  02/19/2025  90 FR 9841   
Final Action  12/00/2025 
Additional Information: DEA Docket number 948
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: Businesses  Federalism: No 
Included in the Regulatory Plan: Yes 
RIN Information URL: DPW@dea.gov   Public Comment URL: www.regulations.gov  
RIN Data Printed in the FR: No 
Agency Contact:
Heather E Achbach
Acting Section Chief, Regulatory Drafting and Support Section
Department of Justice
Drug Enforcement Administration
Diversion Control Division, 8701 Morrissette Drive,
Springfield, VA 22152
Phone:571 387-3185
Email: heather.e.achbach@dea.gov